Almotriptan in the treatment of migraine

Giorgio Sandrini, Armando Perrotta, Natalia L. Arce Leal, Simona Buscone, Giuseppe Nappi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Almotriptan is an orally administered, highly selective serotonin 5-HT(1 B/1 D) receptor agonist that is effective in the acute treatment of moderate to severe migraine attacks. Since its introduction on to the market in 2001, several studies involving a large number of migraine patients have confirmed its efficacy and tolerability profile, Almotriptan, was found to be among the best-responding triptans in terms of pain relief and pain-free rate at 2 h. It has been reported that almotriptan has the best sustained pain-free (SPF) rate and the lowest adverse events (AEs) rate of all the triptans. When these clinical characteristics were combined to form the composite endpoint SPF and no AEs (SNAE), almotriptan emerged as the triptan with the best efficacy and tolerability profile. It also showed a good efficacy profile during the early treatment (within 1 h of onset) of migraine attacks characterized by moderate pain intensity. On the basis of these findings, almotriptan may be considered a therapeutic option for the acute treatment of migraine attacks.

Original languageEnglish
Pages (from-to)799-809
Number of pages11
JournalNeuropsychiatric Disease and Treatment
Volume3
Issue number6
Publication statusPublished - 2007

Fingerprint

Migraine Disorders
Tryptamines
Serotonin
Therapeutics
Pain
almotriptan
Pain-Free

Keywords

  • Almotriptan
  • Migraine
  • Treatment
  • Triptans

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Sandrini, G., Perrotta, A., Arce Leal, N. L., Buscone, S., & Nappi, G. (2007). Almotriptan in the treatment of migraine. Neuropsychiatric Disease and Treatment, 3(6), 799-809.

Almotriptan in the treatment of migraine. / Sandrini, Giorgio; Perrotta, Armando; Arce Leal, Natalia L.; Buscone, Simona; Nappi, Giuseppe.

In: Neuropsychiatric Disease and Treatment, Vol. 3, No. 6, 2007, p. 799-809.

Research output: Contribution to journalArticle

Sandrini, G, Perrotta, A, Arce Leal, NL, Buscone, S & Nappi, G 2007, 'Almotriptan in the treatment of migraine', Neuropsychiatric Disease and Treatment, vol. 3, no. 6, pp. 799-809.
Sandrini G, Perrotta A, Arce Leal NL, Buscone S, Nappi G. Almotriptan in the treatment of migraine. Neuropsychiatric Disease and Treatment. 2007;3(6):799-809.
Sandrini, Giorgio ; Perrotta, Armando ; Arce Leal, Natalia L. ; Buscone, Simona ; Nappi, Giuseppe. / Almotriptan in the treatment of migraine. In: Neuropsychiatric Disease and Treatment. 2007 ; Vol. 3, No. 6. pp. 799-809.
@article{3c97d1d87489478895d2733c756fa519,
title = "Almotriptan in the treatment of migraine",
abstract = "Almotriptan is an orally administered, highly selective serotonin 5-HT(1 B/1 D) receptor agonist that is effective in the acute treatment of moderate to severe migraine attacks. Since its introduction on to the market in 2001, several studies involving a large number of migraine patients have confirmed its efficacy and tolerability profile, Almotriptan, was found to be among the best-responding triptans in terms of pain relief and pain-free rate at 2 h. It has been reported that almotriptan has the best sustained pain-free (SPF) rate and the lowest adverse events (AEs) rate of all the triptans. When these clinical characteristics were combined to form the composite endpoint SPF and no AEs (SNAE), almotriptan emerged as the triptan with the best efficacy and tolerability profile. It also showed a good efficacy profile during the early treatment (within 1 h of onset) of migraine attacks characterized by moderate pain intensity. On the basis of these findings, almotriptan may be considered a therapeutic option for the acute treatment of migraine attacks.",
keywords = "Almotriptan, Migraine, Treatment, Triptans",
author = "Giorgio Sandrini and Armando Perrotta and {Arce Leal}, {Natalia L.} and Simona Buscone and Giuseppe Nappi",
year = "2007",
language = "English",
volume = "3",
pages = "799--809",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",
number = "6",

}

TY - JOUR

T1 - Almotriptan in the treatment of migraine

AU - Sandrini, Giorgio

AU - Perrotta, Armando

AU - Arce Leal, Natalia L.

AU - Buscone, Simona

AU - Nappi, Giuseppe

PY - 2007

Y1 - 2007

N2 - Almotriptan is an orally administered, highly selective serotonin 5-HT(1 B/1 D) receptor agonist that is effective in the acute treatment of moderate to severe migraine attacks. Since its introduction on to the market in 2001, several studies involving a large number of migraine patients have confirmed its efficacy and tolerability profile, Almotriptan, was found to be among the best-responding triptans in terms of pain relief and pain-free rate at 2 h. It has been reported that almotriptan has the best sustained pain-free (SPF) rate and the lowest adverse events (AEs) rate of all the triptans. When these clinical characteristics were combined to form the composite endpoint SPF and no AEs (SNAE), almotriptan emerged as the triptan with the best efficacy and tolerability profile. It also showed a good efficacy profile during the early treatment (within 1 h of onset) of migraine attacks characterized by moderate pain intensity. On the basis of these findings, almotriptan may be considered a therapeutic option for the acute treatment of migraine attacks.

AB - Almotriptan is an orally administered, highly selective serotonin 5-HT(1 B/1 D) receptor agonist that is effective in the acute treatment of moderate to severe migraine attacks. Since its introduction on to the market in 2001, several studies involving a large number of migraine patients have confirmed its efficacy and tolerability profile, Almotriptan, was found to be among the best-responding triptans in terms of pain relief and pain-free rate at 2 h. It has been reported that almotriptan has the best sustained pain-free (SPF) rate and the lowest adverse events (AEs) rate of all the triptans. When these clinical characteristics were combined to form the composite endpoint SPF and no AEs (SNAE), almotriptan emerged as the triptan with the best efficacy and tolerability profile. It also showed a good efficacy profile during the early treatment (within 1 h of onset) of migraine attacks characterized by moderate pain intensity. On the basis of these findings, almotriptan may be considered a therapeutic option for the acute treatment of migraine attacks.

KW - Almotriptan

KW - Migraine

KW - Treatment

KW - Triptans

UR - http://www.scopus.com/inward/record.url?scp=38149128028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149128028&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 799

EP - 809

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

IS - 6

ER -